Raymond James & Associates Purchases 653 Shares of Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE)

Raymond James & Associates raised its position in shares of Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE) by 1.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 50,696 shares of the company’s stock after buying an additional 653 shares during the quarter. Raymond James & Associates owned 1.07% of Invesco Dynamic Biotechnology & Genome ETF worth $2,798,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of PBE. Morgan Stanley grew its stake in shares of Invesco Dynamic Biotechnology & Genome ETF by 6.5% in the third quarter. Morgan Stanley now owns 153,962 shares of the company’s stock worth $9,153,000 after acquiring an additional 9,391 shares during the last quarter. Bank of America Corp DE boosted its stake in Invesco Dynamic Biotechnology & Genome ETF by 55.3% during the fourth quarter. Bank of America Corp DE now owns 95,850 shares of the company’s stock worth $4,511,000 after buying an additional 34,147 shares in the last quarter. PFG Advisors acquired a new stake in Invesco Dynamic Biotechnology & Genome ETF during the fourth quarter worth $1,599,000. Institute for Wealth Management LLC. acquired a new stake in Invesco Dynamic Biotechnology & Genome ETF during the fourth quarter worth $1,107,000. Finally, Stifel Financial Corp boosted its stake in Invesco Dynamic Biotechnology & Genome ETF by 34.4% during the fourth quarter. Stifel Financial Corp now owns 21,776 shares of the company’s stock worth $1,025,000 after buying an additional 5,578 shares in the last quarter.

PBE traded up $0.31 during trading on Monday, reaching $53.83. 9,125 shares of the company’s stock were exchanged, compared to its average volume of 21,803. The firm has a 50 day moving average of $50.75. Invesco Dynamic Biotechnology & Genome ETF has a fifty-two week low of $43.17 and a fifty-two week high of $60.49.

Invesco Dynamic Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.

Further Reading: The mechanics of the bid-ask spread in trading

Institutional Ownership by Quarter for Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE)

Receive News & Ratings for Invesco Dynamic Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Dynamic Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.